sarpogrelate has been researched along with Kidney Failure, Chronic in 1 studies
sarpogrelate: structure given in first source
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hidaka, S | 1 |
| Kobayashi, S | 1 |
| Iwagami, M | 1 |
| Isshiki, R | 1 |
| Tsutsumi, D | 1 |
| Mochida, Y | 1 |
| Ishioka, K | 1 |
| Oka, M | 1 |
| Maesato, K | 1 |
| Moriya, H | 1 |
| Ohtake, T | 1 |
1 trial available for sarpogrelate and Kidney Failure, Chronic
| Article | Year |
|---|---|
Sarpogrelate hydrochloride, a selective 5-HT(2A) receptor antagonist, improves skin perfusion pressure of the lower extremities in hemodialysis patients with peripheral arterial disease.
Topics: Aged; Blood Pressure; Female; Follow-Up Studies; Humans; Kidney Failure, Chronic; Lower Extremity; M | 2013 |